Skip to Content
  • Indexed in
    Scopus
  • 27 days
    Submission to First Decision
  • 7 days
    Acceptance to Publication

Lymphatics

Lymphatics is an international, peer-reviewed, open access journal on lymphatics and related disorders published quarterly online by MDPI.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (144)

  • Review
  • Open Access

Lymphatic disorders encompass a diverse group of congenital and acquired conditions that often first manifest in the skin. Edema, vesicles, verrucous change, erythema, and vascular-appearing lesions overlap with common venous, infectious, neoplastic, and systemic disorders, which makes recognition of lymphatic disease challenging and contributes to diagnostic delay. This review examines the cutaneous manifestations of lymphedema and lymphatic malformations with an emphasis on bedside diagnosis, common mimics, and clinically important pitfalls. We first discuss the clinical evolution of lymphedema and features that distinguish primary from secondary disease, including infectious and oncologic causes and complications. We then review superficial and deep lymphatic malformations, acquired lymphangiectasia, and syndromic disorders including PIK3CA-related overgrowth spectrum and complex lymphatic anomalies. Throughout, we highlight practical clues that can guide imaging, biopsy, genetic evaluation, and multidisciplinary referral.

Lymphatics

10 November 2026

Mild Lymphedema. Adapted from Vargo et al. 2024 under CC BY 4.0 [5].
  • Review
  • Open Access

Acquired lymphatic flow disorders include chylothorax, plastic bronchitis, chylous ascites, protein-losing enteropathy, and post-operative lymphocele. These heterogenous clinical entities share common mechanisms and pathophysiology: disruption to normal antegrade flow of lymphatic fluid. Advances in imaging and interventional techniques have improved physicians’ ability to diagnose and treat these diseases. Workup with computed tomography, heavily T2-weighted MRI, and dynamic contrast-enhanced magnetic resonance lymphangiography can elucidate etiologies and provide targets for intervention. Initial management consists of very-low fat diets, medium chain triglyceride supplementation, and pharmacologic therapy with somatostatin analogs. If conservative management fails, interventions like thoracic duct embolization, thoracic duct stent-grafting and decompression, transjugular intrahepatic porto-systemic shunting, and lymphatic channel embolization offer novel, minimally invasive options, with surgery reserved for refractory cases. Future investigations will establish long-term outcomes after thoracic duct embolization, elucidate the relative benefit of thoracic duct embolization versus stent-grafting, and establish standardized treatment algorithms for post-operative lymphocele. In this review, we discuss the etiologies, workup, diagnosis, and management of acquired lymphatic flow disorders.

Lymphatics

28 October 2026

Cervical chyle leak complicating total laryngectomy with bilateral radical neck dissection in a 52-year-old man. (a–c) Intranodal lymphangiography with transabdominal catheterization of the thoracic duct opacifies the thoracic duct (d,e). Coil and glue embolization of the thoracic duct. After embolization, the right neck drain output decreased to approximately 40 mL/24 h of serous fluid on octreotide and a low-fat diet.
  • Article
  • Open Access

CD4+GM-CSF+ T Cells in Multiple Myeloma Patients

  • Egor Batorov,
  • Tamara Tyrinova and
  • Elena Chernykh
  • + 7 authors

The function of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the development of multiple myeloma (MM) is not clearly elucidated. The aim of this study was to investigate the content of CD4+ helper T cells producing GM-CSF and their possible relationship with monocytic myeloid-derived suppressor cell (M-MDSC) counts in MM patients. The study included 54 MM patients and 10 matched healthy donors. The content of GM-CSF-producing CD4+ T cells and malignant plasma cells (PCs) was assessed by flow cytometry. In vitro expansion of CD4+GM-CSF+ T cells was studied after stimulation with anti-CD3/CD28 or a combination of IL-2, IL-7, and IL-15. CD4+GM-CSF+ T cell counts were higher in MM patients compared to healthy donors. CD4+GM-CSF+ T cell frequency did not differ in the patients achieving remission and the ones with progressive disease. The increase was shown only in patients in remission prior to the conditioning with high-dose melphalan. The relative count of CD4+GM-CSF+ T cells at the engraftment also remained stable. Circulating CD4+GM-CSF+ T cells are inversely correlated with MM PC burden. There were no associations between CD4+GM-CSF+ T cells and M-MDSC counts both before the conditioning and after autologous hematopoietic progenitor cell transplantation. In an in vitro assay, CD4+GM-CSF+ T cells exhibited enhanced proliferation when stimulated with homeostatic cytokines, but not with aCD3/CD28, contrasting with the cultures derived from patients with autoimmune diseases. We did not find evidence supporting a tumor-promoting role for CD4+GM-CSF+ T cells in MM.

Lymphatics

20 October 2026

Circulating CD4+GM-CSF+ T cell counts in multiple myeloma patients. Flow cytometric dot plots for circulating CD4+GM-CSF+ T cells of a representative healthy donor and a multiple myeloma patient are presented (upper right quadrants of dot plots) (A). Relative (B) and absolute (C) counts of circulating CD4+GM-CSF+ T cells of healthy donors (n = 10) and MM patients at successive phases of treatment (in remission following induction therapy prior to the mobilization regimen, n = 15; in remission before the conditioning and auto-HPCT, n = 22; at the engraftment, n = 22; with disease progression, n = 17) are presented. Data are expressed as individual values; lines represent median ± interquartile range values. p values are assessed with the Mann–Whitney U test. HD, healthy donors; PD, progressive disease; Pre-HDM, before the conditioning with high-dose melphalan; Pre-Mob, before the HPC mobilization.
  • Article
  • Open Access

Lymphedema diagnosis is dependent on visual assessment by clinicians. Clinical staging of lymphedema may be complicated by obesity. No quantitative metric is available to measure lymphatic function in patients with both lymphedema and obesity. To address this clinical need, we evaluated nodal uptake percent (NUP) at 120 min in relation to International Society of Lymphology stage and body mass index (BMI). This retrospective study included 20 patients with secondary lower extremity lymphedema, comprising 29 affected and 11 clinically unaffected limbs. NUP was calculated from lymphoscintigraphy. Limb comparisons and receiver operating characteristic (ROC) analyses stratified by BMI were performed. NUP differed among clinically unaffected limbs and ISL stage groups (p = 0.0028). Among patients with BMI < 35 kg/m2, NUP was lower in stage 1 (p = 0.0243) and stage 2 (p = 0.0002) limbs than in unaffected limbs. Among those with BMI ≥ 35 kg/m2, NUP ranged from reduced to preserved values overlapping the unaffected range. In the lower BMI group, the AUC was 0.9792 (95% CI, 0.9309–1.000). A cutoff < 0.4355% yielded 100% sensitivity and 87.5% specificity. NUP demonstrated its potential to complement clinical staging at BMI < 35 kg/m2. However, these findings are hypothesis-generating and require independent external validation.

Lymphatics

17 October 2026

Association between ISL stage and 120 min NUP in (A) the overall cohort and (B) patients with BMI &lt; 35 kg/m2. Each point represents one limb, and horizontal bars indicate medians. Kruskal–Wallis test with Dunn’s multiple-comparison test. * Adjusted p &lt; 0.05; ** adjusted p &lt; 0.01; *** adjusted p &lt; 0.001.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Lymphatics - ISSN 2813-3307